AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26574566 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 224
Study 23864514 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise (vibration amplitude: 1-3 mm; frequency: 6-26 Hz; 4-5 bouts × 60 seconds; 3-5 times weekly)
Number of subjects: 44
Study 23864514 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise
Number of subjects: 44
Study 23864514 — intervention group
Group type: COMPARATOR
Intervention: Usual care and exercises (control group)
Number of subjects: 44
Study 23114193 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond® supplementation after wound closure
Number of subjects: 0
Study 23114193 — intervention group
Group type: COMPARATOR
Intervention: Control group (standardized closure without Dermabond®)
Number of subjects: 0
Study 21859995 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOX (FULV plus oxaliplatin 85 mg/m(2) IV on days 1, 15, and 29 of each cycle)
Number of subjects: 2409
Study 21859995 — intervention group
Group type: COMPARATOR
Intervention: FULV (FU 500 mg/m(2) by IV bolus weekly for 6 weeks; leucovorin 500 mg/m(2) IV weekly for 6 weeks of each 8-week cycle for three cycles)
Number of subjects: 2409
Study 21859995 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOX (FULV plus oxaliplatin)
Number of subjects: 2409
Study 21859995 — intervention group
Group type: COMPARATOR
Intervention: FULV (control)
Number of subjects: 2409
Study 19150573 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-based cytology (SurePath)
Number of subjects: 86469
Study 19150573 — intervention group
Group type: COMPARATOR
Intervention: Conventional cytology
Number of subjects: 86469
Study 17846056 — intervention group
Group type: COMPARATOR
Intervention: 0-1 features of the metabolic syndrome
Number of subjects: 5522
Study 17846056 — intervention group
Group type: EXPERIMENTAL
Intervention: two features of the metabolic syndrome
Number of subjects: 5522
Study 17846056 — intervention group
Group type: EXPERIMENTAL
Intervention: three features of the metabolic syndrome
Number of subjects: 5522
Study 17846056 — intervention group
Group type: EXPERIMENTAL
Intervention: four features of the metabolic syndrome
Number of subjects: 5522
Study 15274382 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month intravenous induction of IFN-alpha2b
Number of subjects: 200
Study 15274382 — intervention group
Group type: COMPARATOR
Intervention: 1 year of adjuvant IFN-alpha2b therapy
Number of subjects: 200
Study 11418367 — intervention group
Group type: EXPERIMENTAL
Intervention: Early consolidation chemotherapy (C-1)
Number of subjects: 195
Study 11418367 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and delayed consolidation chemotherapy (C-1 and C-2)
Number of subjects: 195
Study 11418367 — intervention group
Group type: COMPARATOR
Intervention: Standard maintenance chemotherapy for 2 years
Number of subjects: 195
Study 9564795 — intervention group
Group type: COMPARATOR
Intervention: No supplement
Number of subjects: 38
Study 9564795 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg/day calcium supplement
Number of subjects: 38
Study 9564795 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day cyclical sodium etidronate with 1000 mg/day calcium
Number of subjects: 38
Study 7753886 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (400 mg) administered 60 min before meal (Group C)
Number of subjects: 36
Study 7753886 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (400 mg) administered 5 min before meal (Group A)
Number of subjects: 36
Study 7753886 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (400 mg) administered 30 min before meal (Group B)
Number of subjects: 36
Study 7753886 — intervention group
Group type: COMPARATOR
Intervention: Placebo (400 mg starch)
Number of subjects: 36
Study 2275909 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpleural 0.5% bupivacaine with epinephrine every six hours for a total of four injections
Number of subjects: 26
Study 2275909 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with systemic narcotics alone
Number of subjects: 26
Study 6103440 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 units of whole stored blood at transplantation
Number of subjects: 27
Study 6103440 — intervention group
Group type: COMPARATOR
Intervention: No blood transfusion
Number of subjects: 27
Study 31252651 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee venom (BV)
Number of subjects: 0
Study 28481623 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzu fragrance
Number of subjects: 17
Study 28481623 — intervention group
Group type: COMPARATOR
Intervention: Lavender fragrance
Number of subjects: 17
Study 25828038 — intervention group
Group type: EXPERIMENTAL
Intervention: SGP‐HA (without lidocaine)
Number of subjects: 180
Study 25828038 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 180
Study 23706639 — intervention group
Group type: EXPERIMENTAL
Intervention: Albaconazole 100 mg weekly for 24 or 36 weeks
Number of subjects: 584
Study 23706639 — intervention group
Group type: EXPERIMENTAL
Intervention: Albaconazole 200 mg weekly for 24 or 36 weeks
Number of subjects: 584
Study 23706639 — intervention group
Group type: EXPERIMENTAL
Intervention: Albaconazole 300 mg weekly for 24 or 36 weeks
Number of subjects: 584
Study 23706639 — intervention group
Group type: EXPERIMENTAL
Intervention: Albaconazole 400 mg weekly for 24 or 36 weeks
Number of subjects: 584
Study 23706639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study 21434334 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative medical approach (IMA)
Number of subjects: 141
Study 19609643 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (standard dose)
Number of subjects: 0
Study 19609643 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior vena cava filter placement
Number of subjects: 0
Study 19609643 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17269241 — intervention group
Group type: EXPERIMENTAL
Intervention: CustomCornea
Number of subjects: 58
Study 17269241 — intervention group
Group type: COMPARATOR
Intervention: CustomVue
Number of subjects: 58
Study 15231854 — intervention group
Group type: EXPERIMENTAL
Intervention: Whisky consumption (40 g of alcohol daily for 17 days)
Number of subjects: 23
Study 15231854 — intervention group
Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 23
Study 11920257 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical group (early lung resection)
Number of subjects: 54
Study 11920257 — intervention group
Group type: COMPARATOR
Intervention: Medical group (antifungal drugs)
Number of subjects: 54
Study 9621526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein mesh repair (n = 42)
Number of subjects: 80
Study 9621526 — intervention group
Group type: COMPARATOR
Intervention: modified Bassini repair (n = 38)
Number of subjects: 80
Study 9621526 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 80
Study 7936512 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide (3.75 mg/month)
Number of subjects: 25
Study 7936512 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study 1979687 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0
Study 1979687 — intervention group
Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 0
Study 572699 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser treatment
Number of subjects: 0
Study 572699 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton laser treatment
Number of subjects: 0
Study 572699 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31714573 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF therapy
Number of subjects: 10051
Study 31714573 — intervention group
Group type: COMPARATOR
Intervention: Emergency admission for UC
Number of subjects: 10051
Study 31714573 — intervention group
Group type: COMPARATOR
Intervention: Period comparison 2007-2011 vs 2012-2017
Number of subjects: 10051
Study 31714573 — intervention group
Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 10051
Study 31714573 — intervention group
Group type: COMPARATOR
Intervention: Increased comorbidity, lower deprivation, high provider volume of colectomies for UC
Number of subjects: 10051
Study 31714573 — intervention group
Group type: COMPARATOR
Intervention: Female sex and Asian ethnicity
Number of subjects: 10051
Study 31835387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergomotor intervention (integrated program with tailor-made motor control training and ergonomic advice for 12 weeks)
Number of subjects: 101
Study 31835387 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care with conventional physiotherapy for 12 weeks)
Number of subjects: 101
Study 28349271 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaeagnus
Number of subjects: 75
Study 28349271 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaeagnus/Boswellia
Number of subjects: 75
Study 28349271 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 75
Study 25834682 — intervention group
Group type: EXPERIMENTAL
Intervention: US Simulator Skills Training
Number of subjects: 36
Study 25834682 — intervention group
Group type: COMPARATOR
Intervention: Traditional Skills Training
Number of subjects: 36
Study 25834682 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Skills Training Plus US Simulator Skills Training
Number of subjects: 36
Study 25834682 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups pre- and post-course
Number of subjects: 36
Study 23250116 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day probiotics regimen
Number of subjects: 115
Study 23250116 — intervention group
Group type: COMPARATOR
Intervention: 7-day metronidazole regimen
Number of subjects: 115
Study 22480099 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg elemental iron once per week
Number of subjects: 100
Study 22480099 — intervention group
Group type: COMPARATOR
Intervention: 100 mg elemental iron daily (group I)
Number of subjects: 100
Study 22480099 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg elemental iron once per week (group II)
Number of subjects: 100
Study 19440906 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage-matched message intervention
Number of subjects: 130
Study 19440906 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic message intervention
Number of subjects: 130
Study 19440906 — intervention group
Group type: COMPARATOR
Intervention: Control group (lectures only)
Number of subjects: 130
Study 17316434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention (group programme)
Number of subjects: 0
Study 15531624 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery for six bottles of champagne
Number of subjects: 0
Study 15531624 — intervention group
Group type: EXPERIMENTAL
Intervention: One chance of six bottles
Number of subjects: 0
Study 15531624 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest incentive
Number of subjects: 0
Study 11560881 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/day for 8 weeks
Number of subjects: 4
Study 11560881 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 100 mg/day
Number of subjects: 4
Study 11560881 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide doses greater than 100 mg/day
Number of subjects: 4
Study 11560881 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 4
Study 9786163 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride infusion
Number of subjects: 14
Study 9786163 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study 7943769 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 31
Study 7943769 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 31
Study 31313855 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week sexual rehabilitation programme
Number of subjects: 10
Study 30461604 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Digital Storytelling (REDStory) therapy for 8 weeks
Number of subjects: 80
Study 30461604 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 80
Study 27038001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 45 mg
Number of subjects: 36
Study 27038001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg
Number of subjects: 36
Study 27038001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Number of subjects: 36
Study 27038001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (45, 60, and 90 mg)
Number of subjects: 36
Study 27038001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (45 and 90 mg)
Number of subjects: 36
Study 27038001 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 36
Study 25545196 — intervention group
Group type: EXPERIMENTAL
Intervention: OAS with ICAPS R(®) - Alcon Laboratories, n = 26
Number of subjects: 117
Study 25545196 — intervention group
Group type: EXPERIMENTAL
Intervention: OAS without ω‐3 fatty acids (OFTAN MACULA(®) - Laboratorios Esteve, n = 28)
Number of subjects: 117
Study 25545196 — intervention group
Group type: COMPARATOR
Intervention: Control group without OAS, n = 63
Number of subjects: 117
Study 24060942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanotic CHD
Number of subjects: 47218
Study 24060942 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocardial cushion defects
Number of subjects: 47218
Study 24060942 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-sided lesions
Number of subjects: 47218
Study 24060942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac surgery within 6 months
Number of subjects: 47218
Study 24060942 — intervention group
Group type: EXPERIMENTAL
Intervention: Age <3 years
Number of subjects: 47218
Study 20875492 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole inactivated Mycobacterium vaccae (MV)
Number of subjects: 2013
Study 20875492 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2013
Study 18367035 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid angioplasty with stent placement
Number of subjects: 0
Study 16824833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pactimibe, 100 mg daily for 18 months
Number of subjects: 534
Study 16824833 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 18 months
Number of subjects: 534
Study 14700149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (3 doses at 24-hour intervals)
Number of subjects: 30
Study 14700149 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (3 doses at 12-hour intervals)
Number of subjects: 30
Study 11042920 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who received questionnaires requesting consent to collect data from clinical records.
Number of subjects: 5069
Study 11042920 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 5069
Study 8798051 — intervention group
Group type: EXPERIMENTAL
Intervention: Visipaque
Number of subjects: 0
Study 8798051 — intervention group
Group type: COMPARATOR
Intervention: Omnipaque
Number of subjects: 0
Study 8798051 — intervention group
Group type: COMPARATOR
Intervention: monomeric CM
Number of subjects: 0
Study 1633722 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated naproxen
Number of subjects: 123
Study 1633722 — intervention group
Group type: COMPARATOR
Intervention: Standard naproxen
Number of subjects: 123
Study 6511139 — intervention group
Group type: EXPERIMENTAL
Intervention: Distilled beverage
Number of subjects: 60
Study 6511139 — intervention group
Group type: EXPERIMENTAL
Intervention: Brewed beverage
Number of subjects: 60
Study 6511139 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled)
Number of subjects: 60
Study 6511139 — intervention group
Group type: COMPARATOR
Intervention: Placebo (brewed)
Number of subjects: 60
Study 30849533 — intervention group
Group type: EXPERIMENTAL
Intervention: Email completion of NDI and JOA questionnaires
Number of subjects: 206
Study 30849533 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone completion of NDI and JOA questionnaires before in-office administration
Number of subjects: 206
Study 30849533 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office administration followed by phone completion of NDI and JOA
Number of subjects: 206
Study 30849533 — intervention group
Group type: EXPERIMENTAL
Intervention: Email versions of NDI and JOA
Number of subjects: 206
Study 30849533 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone-before-office versions of NDI and JOA
Number of subjects: 206
Study 30849533 — intervention group
Group type: EXPERIMENTAL
Intervention: Office-before-phone versions of NDI and JOA
Number of subjects: 206
Study 30849533 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up phone reminders for email administration of NDI and JOA
Number of subjects: 206
Study 30849533 — intervention group
Group type: COMPARATOR
Intervention: Completion rates between email and in-office questionnaire completion
Number of subjects: 206
Study 30849533 — intervention group
Group type: COMPARATOR
Intervention: Completion rates between phone-before-office and in-office questionnaire completion
Number of subjects: 206
Study 29984912 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodynamically optimized dual chamber His‐bundle pacing
Number of subjects: 160
Study 29984912 — intervention group
Group type: COMPARATOR
Intervention: Backup pacing only (using the non‐His ventricular lead)
Number of subjects: 160
Study 26630997 — intervention group
Group type: COMPARATOR
Intervention: Contrast concentration of 300 mgI/mL
Number of subjects: 60
Study 26630997 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast concentration of 240 mgI/mL
Number of subjects: 60
Study 26630997 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast concentration of 140 mgI/mL
Number of subjects: 60
Study 24947583 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day (n = 26)
Number of subjects: 50
Study 24947583 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (n = 24)
Number of subjects: 50
Study 22540534 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person follow-up
Number of subjects: 245
Study 22540534 — intervention group
Group type: COMPARATOR
Intervention: No in-person follow-up
Number of subjects: 245
Study 19385713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11 for two 21-day cycles plus omeprazole 40 mg on days 6-10 and day 8 of cycle 1 or 2.
Number of subjects: 27
Study 19385713 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib 1.3 mg/m2 on days 1, 4, 8 and 11 for two 21-day cycles without omeprazole (control).
Number of subjects: 27
Study 19385713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib with omeprazole.
Number of subjects: 27
Study 18459902 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-guided stereotactic biopsy
Number of subjects: 20
Study 18459902 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-guided trajectories
Number of subjects: 20
Study 18459902 — intervention group
Group type: EXPERIMENTAL
Intervention: PET data
Number of subjects: 20
Study 16236558 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure therapy (cognitive-behavioral therapy for PTSD)
Number of subjects: 384
Study 16236558 — intervention group
Group type: COMPARATOR
Intervention: Present-centered therapy (comparison treatment)
Number of subjects: 384
Study 16236558 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure therapy
Number of subjects: 384
Study 16236558 — intervention group
Group type: COMPARATOR
Intervention: Present-centered therapy
Number of subjects: 384
Study 11911726 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized telephonic case-management intervention for 6 months
Number of subjects: 358
Study 11911726 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 358
Study 9512881 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective eligibility criteria
Number of subjects: 224
Study 9512881 — intervention group
Group type: COMPARATOR
Intervention: Objective eligibility criteria
Number of subjects: 224
Study 7618707 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 52
Study 7618707 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard transfusion therapy)
Number of subjects: 52
Study 2096487 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous DDAVP (0.3 microgram/kg)
Number of subjects: 10
Study 2096487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 361201 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA assay with levels above 9 ng/ml
Number of subjects: 377
Study 361201 — intervention group
Group type: COMPARATOR
Intervention: CEA assay with levels less than 9 ng/ml
Number of subjects: 377
Study 361201 — intervention group
Group type: COMPARATOR
Intervention: Radionuclide liver scan
Number of subjects: 377
Study 361201 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA assay
Number of subjects: 377
Study 30561287 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional cash transfers (UCT) of 10,000 XOF monthly from July to November 2013 and 2014
Number of subjects: 1143
Study 30561287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cash transfers)
Number of subjects: 1143
Study 27473182 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental in-person EQUIP training with active feedback at 5 sites
Number of subjects: 22316
Study 27473182 — intervention group
Group type: COMPARATOR
Intervention: Control sites (4 sites) without training or feedback
Number of subjects: 22316
Study 26090428 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day nonbismuth containing quadruple therapy (EACM)
Number of subjects: 200
Study 26090428 — intervention group
Group type: COMPARATOR
Intervention: 7-day standard triple therapy (EAC)
Number of subjects: 200
Study 24267042 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (18 g/d) and isoflavone tablets (105 mg/d isoflavone aglycone equivalents)
Number of subjects: 131
Study 24267042 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein and placebo tablets
Number of subjects: 131
Study 24267042 — intervention group
Group type: EXPERIMENTAL
Intervention: Control protein and isoflavone tablets
Number of subjects: 131